TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-25

Study Completion Date

2027-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open-label, phase 1 trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs in metastatic melanoma patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma

NCT04217473

Metastatic Melanoma

COMPLETED PHASE1

Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma

NCT06961357

Melanoma

RECRUITING PHASE1/PHASE2

Vemurafenib and TIL Therapy for Metastatic Melanoma

NCT02354690

Metastatic Melanoma

COMPLETED PHASE1/PHASE2

T-cell Based Immunotherapy for of Melanoma

NCT00937625

Melanoma

COMPLETED PHASE1/PHASE2

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

NCT05628883

Metastatic Melanoma Unresectable Melanoma Acral Melanoma +7 more

ACTIVE_NOT_RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

TILT-123 is a tumor-selective replicating oncolytic adenovirus expressing TNFa and IL-2 that is being investigated in several Phase 1 clinical studies in patients with various types of cancer. This is the second study of TILT-123 in patients with metastatic melanoma. Building upon the previous study, TILT-T215, which evaluated the safety and preliminary efficacy of TILT-123 in combination with TILs, Study TILT-T216 will investigate the addition of lymphocyte-depleting chemotherapy to the combination of TILT-123 and TILs. The purpose of lymphodepleting chemotherapy, cyclophosphamide and fludarabine phosphate is to reduce irrelevant T cells and eliminate the regulatory T cells, which are known to be able to inhibit T-cell mediated tumor cell killing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TILT-123, TILs and chemotherapy

TILT-123 in combination with lymphocyte-depleting chemotherapy and TILs

Group Type EXPERIMENTAL

TILT-123

Intervention Type BIOLOGICAL

TNFalpha and IL-2 coding oncolytic adenovirus TILT-123

TIL

Intervention Type BIOLOGICAL

Adoptive T cell therapy with TILs

Cyclophosphamide

Intervention Type DRUG

Lymphocyte-depleting chemotherapy

Fludarabine

Intervention Type DRUG

Lymphocyte-depleting chemotherapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TILT-123

TNFalpha and IL-2 coding oncolytic adenovirus TILT-123

Intervention Type BIOLOGICAL

TIL

Adoptive T cell therapy with TILs

Intervention Type BIOLOGICAL

Cyclophosphamide

Lymphocyte-depleting chemotherapy

Intervention Type DRUG

Fludarabine

Lymphocyte-depleting chemotherapy

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ad5/3-E2F-d24-hTNFa-IRES-hIL2 Tumor-infiltrating lymphocytes Cytoxan cyclophosphane Fludara

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients must be 18 to 75 years of age inclusive, at the time of signing the informed consent.
2. Patients with pathologically confirmed previously treated refractory or recurrent stage 3-4 melanoma, which cannot be treated with curative intent with available therapies.
3. Patients who have had at least 1 prior line of medical treatment (eg, checkpoint inhibitors, kinase inhibitors, IL-2). Multiple prior therapies (eg, surgery, checkpoint inhibitors, kinase inhibitors, IL-2, interferon, chemotherapy, radiation) are allowed.
4. Patients must have a demonstrated WHO/ECOG performance score of 0-1 at screening.
5. A tumor of \>9 mm in diameter (typically a minimum of 1 cm3 in volume), without signs of necrosis, must be available for biopsy/operation to enable growing of TILs.
6. At least 1 additional tumor (\>14 mm in diameter) must be available for injections and biopsies for correlative analyses. The disease burden must be evaluable according to RECIST 1.1.
7. Patients must have adequate hepatic, cardiac, and renal function as follows:

1. Platelets ≥ 100,000/µl and \< 700,000/µl
2. Hemoglobin ≥100 g/L
3. AST and ALT ≤2.5×ULN
4. GFR \>60 mL/min (CKD-EPI)
5. Leukocytes (WBC) \>3.0G/L
6. Absolute neutrophil count greater than 1500/mm3 without the support of filgrastim
7. Bilirubin \<1.5×ULN
8. Patients of 60 years or older, or have a history of ischemic heart disease, chest pain, or clinically significant atrial and/or ventricular arrhythmias including but not limited to: atrial fibrillation, ventricular tachycardia, heart block, will undergo cardiac evaluation: LVEF assessment with documented LVEF ≥ 50% by either TTE (trans thoracal echocardiography) or MUGA (multigated acquisition scan). Further cardiac evaluations in patients with cardiac risk factors (e.g. diabetes, hypertension, obesity) will be evaluated by the investigator as deemed necessary.
8. Must be willing to use adequate forms of contraception from screening, during the study, and for a minimum of 90 days after the end of treatment, in accordance with the following:

1. Woman of childbearing potential: Barrier contraceptive method (ie, condom) must be used in addition to 1 of the following methods: Intrauterine devices or hormonal contraception (oral contraceptive pills, implants, transdermal patches, vaginal rings or long-acting injections).
2. Women not of childbearing potential: Barrier contraceptive method (ie, condom) must be used.
3. Men: Barrier contraceptive method (ie, condom) must be used.
9. Patients must be capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
10. Patients must be capable of understanding and complying with the parameters outlined in the protocol.
11. Patients must have a life expectancy longer than 3 months.
12. Patients must be eligible for adoptive T-cell therapy with Lymphocyte-depleting chemotherapy and TILs.

Exclusion Criteria

1. History of another active invasive cancer as judged by the investigator within the past 3 years except basal cell carcinoma.
2. Uncontrolled cardiac or vascular diseases.
3. History of heart attack or cerebral stroke within the previous 12 months before screening or is not recovered from a previous heart attack or cerebral stroke.
4. History of hepatic dysfunction, hepatitis, or human immunodeficiency virus.

1. Patients should be seronegative for HIV antibody.
2. Patients should be seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.
5. History of coagulation disorder.
6. Untreated brain metastases. Treated brain metastases that have not progressed in the 3 months prior to screening are allowed.
7. Concurrent opportunistic and/or active systemic infections.
8. Use of immunosuppressive medications (corticosteroids or drugs used in treatment of autoimmune disease), except for the following, which can be allowed at screening and during the study:

1. Replacement corticosteroids (eg, if the patient has adrenal insufficiency after prior immunotherapy)
2. Pulmonary and topical treatments
3. Prednisone/prednisolone at doses up to 20 mg/day
9. Treated with any anticancer therapy (eg, immunotherapy, signal-transduction inhibitors \[eg. BRAF and MEK inhibitors\], cytotoxic chemotherapy, radiotherapy, or investigational agents \[ie, any drug or therapy that is currently not approved for use in humans\]) within 30 days prior to enrollment.
10. Previously treated with any oncolytic adenovirus that was administered IT.
11. Previously treated with adoptive cell therapy.
12. Administered an IMP or device in another clinical study within 30 days prior to baseline.
13. Lactate dehydrogenase value \>5×ULN.
14. Allergy to any ingredients present in the IMPs (as listed in the respective IBs).
15. Women of childbearing potential who are pregnant, breastfeeding, or intending to become pregnant.
16. Any other medical condition or laboratory abnormality that, in the judgment of the principal investigator, could increase the risk associated with study participation, interfere with interpretation of study results, or otherwise render study participation inappropriate.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No